Martha Sajatovic, MD Professor of Psychiatry and of Neurology Willard Brown Chair in Neurological Outcomes Research Director, Neurological Outcomes Center University Hospitals Case Medical Center Cleveland, OH
Additional Content Development Faculty Bradley N. Gaynes, MD, MPH Professor of Psychiatry Associate Chair for Research Training and Education University of North Carolina School of Medicine Chapel Hill, NC
J. Craig Nelson, MD Professor in Residence Department of Psychiatry Leon J Epstein M.D. Chair in Geriatric Psychiatry Director of Geriatric Psychiatry University of California-San Francisco San Francisco, CA
Michael Thase, MD Professor of Psychiatry Perelman School of Medicine University of Pennsylvania School of Medicine Philadelphia, PA
Albert Einstein CCME Reviewer Gregory Asnis, MD Professor, Department of Psychiatry and Behavioral Sciences Montefiore Medical Center Bronx, NY
NOTE: This activity was presented as a live visiting faculty grand rounds series on 17 occasions between January 29, 2014 and June 26, 2014. Participants who received credit for attending any of the live presentations are not eligible to receive credit for this online release.
Numerous treatments are available for the management of MDD, yet many patients do not obtain relief from their symptoms because they fail to respond adequately to these medications or experience intolerable side effects. Several educational gaps exist that serve as barriers to helping these patients receive effective treatment for their MDD. Psychiatrists and primary care clinicians require guidance to develop optimal individualized MDD treatment approaches based on the most current evidence. The goal of this activity is to expand knowledge, skills, and competency among psychiatrists and primary care clinicians regarding current and emerging treatment options for MDD, ultimately helping them achieve the best possible outcomes for each patient with MDD. Program Developer/Facilitator
This activity is jointly provided by Albert Einstein College of Medicine and Montefiore Medical Center, and MCM Education.
This activity has been designed for psychiatrists, internal medicine and primary care clinicians, and other clinicians interested and involved in the treatment of patients with MDD.
Upon completion of this educational activity, the participant should be able to:
Effectively use rating scales to assess patient response to depression treatment and medication side effects.
Develop evidence-based treatment plans for individual patients to manage acute symptoms of depression.
Tailor treatment based on diagnostic considerations, treatment adherence, and medication side effects.
Determine how existing and novel approaches for treatment of residual symptoms of depression can be applied to real-world tailored treatment.
Discuss the mechanism of action and emerging data on investigational agents for depression.
The “Conflict of Interest Disclosure Policies” of Albert Einstein College of Medicine of Yeshiva University require that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience any relationship(s) with a pharmaceutical or equipment company. Any presenter whose disclosed relationships prove to create a conflict of interest, with regard to their contribution to the activity, will not be permitted to present.
The Albert Einstein College of Medicine of Yeshiva University (Einstein) also require that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience when discussing any unlabeled or investigational use of any commercial product, or device, not yet approved for use in the United States.
Contributors whose COIs are irresolvable are not permitted to participate in Einstein CME activities.
Martha Sajatovic, MD
Grant/Research: Pfizer, Merck, Ortho-McNeil Janssen, Reuter Foundation, Woodruff Foundation, Reinberger Foundation, National Institutes of Health (NIH), Centers for Disease Control (CDC)
Consultant: United BioSource Corporation, Prophase, Otsuka, Pfizer, Amgen
Royalties: Springer Press, Johns Hopkins University Press, Oxford Press, Lexicomp
Bradley N. Gayness, MD, MPH
Nothing to disclose
J. Craig Nelson, MD
Grant Research: National Institute of Mental Health, Health Resources and Services Administration (HRSA)
Consultant/Speakers Bureau: BMS, Cenestra Health, Corcept, Eli Lilly and Company, Medtronic, Mylan (Dey Pharma), Otsuka, Pfizer, Sunovion, Theracos
Honoraria: Otsuka Asia
Advisory Board: Eli Lilly and Company, Shire, Sunovion
Stock Ownership: Atossa
Michael Thase, MD
Grant Support: Agency for Healthcare Research and Quality, Eli Lilly and Company, Forest Pharmaceuticals, National Institute of Mental Health, Otsuka
Consultant/Advisory: Alkermes, AstraZeneca, BMS, Eli Lilly and Company, Dey Pharma, L.P., Forest Laboratories (including PGx), Gerson Lehman Group, GSK, Guidepoint Global, H. Lundbeck A/S, MedAvante, Inc., Merck (including Schering-Plough Corporation and Organon), Neuronetics, Inc., Ortho-McNeil Pharmaceuticals (including Johnson & Johnson), Otsuka, Pfizer (including Wyeth Ayerst Pharmaceuticals), Roche, Shire US Inc., Sunovion Pharmaceuticals, Inc., Takeda, Transcept Pharmaceuticals
Honoraria: AstraZeneca, BMS, Eli Lilly and Company., Merck and Co. Inc., Pfizer (including Wyeth Ayerst Pharmaceuticals)
Equity Holdings: MedAvante, Inc.
Royalties: American Psychiatric Foundation, Guilford Publications, Herald House, W.W. Norton & Company, Inc.
Spouse’s Employment: Peloton Advantage (Formerly Advogent and Embryon), does business with Pfizer/Wyeth)
Gregory Asnis, MD:
Nothing to disclose
The staff of the Center for Continuing Medical Education at Albert Einstein College of Medicine and Montefiore Medical Center and MCM Education have nothing to disclose.
ACCME ACCREDITATION STATEMENT: This activity has been planned and implemented in accordance with the Requirements of the ACCME through joint providership of Albert Einstein College of Medicine of Yeshiva University, Montefiore Medical Center, and MCM Education. Albert Einstein College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
ACCME CREDIT DESIGNATION STATEMENT: Albert Einstein College of Medicine of Yeshiva University designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit TM. Physicians should claim only the credit commensurate with the extent of their participation in each activity. Commercial Support Statements
Funded by independent educational grants from Takeda Pharmaceuticals International, Inc., U.S. Region and Lundbeck, and Otsuka America Pharmaceutical, Inc.
Presented by Albert Einstein College of Medicine & Montefiore Medical Center, Center for Continuing Medical Education and MCM Education.
The opinions expressed in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, Albert Einstein College of Medicine & Montefiore Medical Center, Center for Continuing Medical Education, MCM Education, Takeda Pharmaceuticals International, Inc., U.S. Region and Lundbeck, or Otsuka America Pharmaceutical, Inc. Any medications, diagnostic procedures, or treatments discussed by the faculty should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.